Psychedelic therapy is emerging as a potential treatment for depression, with increasing interest in its use within the NHS. Participants in clinical trials are exploring substances like psilocybin and DMT, which are currently classified as Schedule 1 drugs in the UK. Early findings suggest that these therapies may help individuals process difficult emotions and thoughts, although researchers caution that they are not a cure-all.
Experts emphasize the importance of regulated settings for treatment, as unregulated practices can pose significant risks. The Royal College of Psychiatrists supports further research into psychedelic-assisted therapy, highlighting its potential benefits for patients who do not respond to traditional treatments.